Click here to close now.




















Welcome!

News Feed Item

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H2, 2014" provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Multiple Sclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Sclerosis 25
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36

Prominent Sponsors 37
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Multiple Sclerosis 41
Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 41
May 27, 2014: Bionure MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay 41
Clinical Trial Profiles 43
Clinical Trial Overview of Top Companies 43
Biogen Idec Inc. 43
Clinical Trial Overview of Biogen Idec Inc. 43
E. Merck KG 53
Clinical Trial Overview of E. Merck KG 53
Novartis AG 59
Clinical Trial Overview of Novartis AG 59
Teva Pharmaceutical Industries Limited 64
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 64
Bayer AG 68
Clinical Trial Overview of Bayer AG 68

Sanofi 72
Clinical Trial Overview of Sanofi 72
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Acorda Therapeutics, Inc. 77
Clinical Trial Overview of Acorda Therapeutics, Inc. 77
Elan Corporation, plc 79
Clinical Trial Overview of Elan Corporation, plc 79
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Clinical Trial Overview of Top Institutes / Government 81
National Institute of Neurological Disorders and Stroke 81
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 81
Charite - Universitatsmedizin Berlin 83
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 83
Tehran University of Medical Sciences 84
Clinical Trial Overview of Tehran University of Medical Sciences 84
U.S. Department of Veterans Affairs 85
Clinical Trial Overview of U.S. Department of Veterans Affairs 85
Oregon Health & Science University 86
Clinical Trial Overview of Oregon Health & Science University 86
The National Institute of Allergy and Infectious Diseases 87

Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
University of Washington 88
Clinical Trial Overview of University of Washington 88
St. Andrea Hospital Sapienza Rome University 89
Clinical Trial Overview of St. Andrea Hospital Sapienza Rome University 89
Imperial College London 90
Clinical Trial Overview of Imperial College London 90
Department of Health, UK 91
Clinical Trial Overview of Department of Health, UK 91
Five Key Clinical Profiles 92
Appendix 196
Abbreviations 196
Definitions 196
Research Methodology 197
Secondary Research 197
About GlobalData 198
Contact Us 198
Disclaimer 198
Source 198

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 53
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 59

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 64
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 68
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 72
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 77
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Elan Corporation, plc, 2014* 79
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 81
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 83
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 84
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 85

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health & Science University, 2014* 86
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 88
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Andrea Hospital Sapienza Rome University, 2014* 89
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 90
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 91

List of Figures

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 197

To order this report: Multiple Sclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes ab...
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...